生命科学与医疗健康
FBC在生命科学领域具备全面的专业知识，在诸多领域为最知名的跨国公司和本土企业提供服务，包括各个发展阶段的生物制药、生物技术、医疗设备、医疗服务、基因组学、诊断学、医用信息技术和健康护理服务等企业。FBC的客户包括医疗设备和生物技术初创企业，也包括国际大型制药公司，以及专注于生命科学和健康护理公司的风险投资基金。
FBC为生命科学公司提供涉及公募、私募和债务融资、兼并与收购、研发融资、技术许可和日常事项的法律咨询。
FBC就生命科学与医疗健康的监管事务提供法律服务，包括药物、生物科技和医疗器械等领域。我们就卫生部的要求和许可程序提供合规建议，包括注册、标签、进口、生产、药品安全（药物警戒）和产品责任，以及医药产品在以色列的营销，等。
FBC的专业人员与该领域最活跃的风险投资基金、战略投资者和私人投资者保持密切联系，并利用FBC的关系网络服务客户。
Perrigo, a NYSE and TASE-traded company, in the Israeli aspects of its proxy fight against Mylan N.V.’s hostile takeover, the $8.6B acquisition of Elan Corporation and the reincorporation of Perrigo in Ireland, and in its earlier acquisition of Agis Industries
OrbiMed Fund, the world’s largest life sciences-dedicated fund, in certain Israeli law aspects of fund formation matters, various investments in public and private Israeli life science companies
Kamada, an Israeli publicly traded pharmaceutical company, in a $200M distribution, manufacturing and license agreement with Baxter and a $200M strategic distribution agreement with Chiesi Farmaceutici
Rainbow Fund, in a variety of strategic and financial transactions with leading players such as Medtronic, Abbott Laboratories, Sorin Group and Sony
Natali-Seculife Israel, Israel’s leading provider of emergency telemedicine and home help services to senior citizens and people requiring cardiac monitoring
Clal Biotechnology
